Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220026/S016

Symplicity Spyral Renal Denervation Catheter

Medtronic, Inc. · Decision date Mar 25, 2026

FDA DECISIONP220026/S016

What did the FDA decide?

FDA records P220026/S016 as a supplement to PMA P220026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 25, 2026.

An approval order statement is not included in the imported record. Open the FDA listing for the decision documents.

Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Mar 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220026/S016
Regulatory pathway
PMA supplement
Product code
QYI
Decision code
OK30
Decision date
Mar 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220026 · Original PMA

    Symplicity Spyral Renal Denervation System

  2. P220026/S016 received

    Application receipt date recorded by FDA.

  3. P220026/S015 · Related supplement

    Symplicity Spyral Multi-Electrode Renal Denervation Catheter

  4. P220026/S016 · FDA decision

    30-Day Notice

  5. P220026/S017 · Related supplement

    Symplicity Spyral Renal Denervation System

  6. P220026/S014 · Related supplement

    Symplicity Spyral Renal Denervation System

  7. P220026/S019 · Related supplement

    Symplicity G3 Renal Denervation RF Generator

Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalNov 17, 2023FDA
Medtronic, Inc.PMA supplementFeb 27, 2026FDA
Medtronic, Inc.PMA supplementJul 16, 2026FDA
Medtronic, Inc.PMA supplementSep 10, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code QYI

Product / regulatory recordCompanyPathwayDecision dateSource
Recor Medical, Inc.PMA supplementAug 13, 2026FDA
Recor Medical, Inc.PMA supplementJul 29, 2026FDA
Recor Medical, Inc.PMA supplementSep 11, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records